1 / 30

ARRITMIAS Ignacio Fernández Lozano. Javier Alzueta.

This study compares the efficacy and safety of dronedarone and amiodarone for treating atrial fibrillation patients. It includes risk stratification for syncope and sudden death incidence. Results from a global population with various risk factors are analyzed.

ray
Download Presentation

ARRITMIAS Ignacio Fernández Lozano. Javier Alzueta.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ARRITMIAS Ignacio Fernández Lozano.Javier Alzueta.

  2. FA

  3. 402 PT

  4. 1.376 PT

  5. 5.700 PT CHADS FAPx 1,8 FAPn 2

  6. 627 PT

  7. 4.628 PT

  8. Purpose The objective of this study is to compare the efficacy and safety of dronedarone to that of amiodarone for the treatment of patients with atrial fibrillation. 504 PT

  9. 112 PT

  10. SINCOPE

  11. Estratificación de riesgo

  12. 504 PT

  13. Incidencia de Muerte súbita Myerburg RJ. Circulation.1998;97:1514-1521. GROUP Población global >2 factores de riesgo Pacientes con enfermedad coronaria Pacientes con FE <35%, e ICC Pacientes con PCR previa Pacientes con IAM FE deprimida y TV 0 0 100,000 200,000 300,000 5 10 20 25 30 Incidencia de MS(% grupo) Nº. De MS anual

  14. High energy implant rates pmp Source: Eucomed

  15. 490 PT

  16. 651 PT

  17. 206 PT

  18. 45 PT

  19. 7.001 PT

More Related